Single dose intravenous injection of BBM-H901

GENETIC2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Shanghai Xinzhi BioMed Co., Ltd.

Conditions

Hemophilia B

Phase 2

Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

Active, not recruitingNCT05203679

Shanghai Xinzhi BioMed Co., Ltd.Hemophilia B

Start: 2021-12-30End: 2028-06-30Updated: 2026-04-01

Unknown Phase

Gene Therapy for Chinese Hemophilia B

CompletedNCT04135300

Institute of Hematology & Blood Diseases Hospital, ChinaHemophilia B

Start: 2019-10-16End: 2022-01-07Updated: 2025-02-21

Related Papers

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials.

2025-11-201 citations

Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia

Blood2025-11-03

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

Blood2024-11-052 citations

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.

2022-05-1954 citations